

Comparison of Leucocyte Telomere Length, Atherosclerotic Cardiovascular disease risk and the output of a Deep learning Cardiac BioAge risk prediction tool: A UK Biobank Cohort study

Ehsan Vaghefi^{1,3*}, Songyang An^{1,3}, Rini Corbett³, David Squirrell^{2,3}

1. Department of Optometry and Ophthalmology, University of Auckland, New Zealand
2. Department of Ophthalmology, Greenlane Clinical Centre, Auckland District Health Board, Auckland
3. Toku Eyes, Auckland, New Zealand

* Corresponding author

Associate Professor Ehsan Vaghefi

6 Clayton Street, New Market

Auckland

New Zealand, 1023

e.vaghefi@auckland.ac.nz

Abstract.

Significance.

That a retinal image based Deep Learning (DL) Cardiac BioAge Model may be a useful novel tool that can personalise an individual's risk of Atherosclerotic cardiovascular disease (ASCVD) events.

Purpose.

To determine whether the results issued by our DL Cardiac BioAge model are consistent with the known trends of cardiovascular disease (CVD) risk and the biomarker Leucocyte Telomere Length, in a cohort of individuals from the UK Biobank.

Methods.

Individuals were divided by sex, ranked by Z adjusted log T/S Leucocyte Telomere length (LTL) and then grouped into deciles. The retinal images were then presented to the DL model and individual's Cardiac BioAges determined. Individuals within each LTL decile was then ranked by Cardiac BioAge, and the mean of the CVD risk biomarkers in the top and bottom quartiles compared. The relationship between an individual's Cardiac BioAge, the CVD biomarkers and LTL were determined using traditional correlation statistics.

Results.

The DL Cardiac BioAge model was able to accurately stratify individuals by the traditional CVD risk biomarkers, and for both males and females those issued with a Cardiac BioAge in the top quartile of their chronological peer group had a significantly higher mean SBP, HbA1C and 10-year Pooled Cohort Equation ASCVD scores compared to those individuals in the bottom quartile. Cardiac BioAge was associated with LTL shortening for both males and females. (Males: -0.220 , $P < 0.001$; Females: -0.174 , $P < 0.001$)

Conclusion

In this small cohort study increasing CVD risk; as assessed by both traditional biomarkers, ASCVD risk scoring and a DL Cardiac BioAge CVD risk model, was inversely related to LTL. At a population level our data supports the growing body of evidence that suggests that LTL shortening is a surrogate marker for increasing CVD risk and that this risk can be captured by our novel DL Cardiac BioAge model.

Key Words.

Deep learning, Cardiac BioAge, Leucocyte Telomere Length, Cardiovascular risk

Introduction:

Atherosclerotic Cardiovascular disease (ASCVD) is the commonest cause of hospitalization and premature death in the US¹. The risk of an individual experiencing an ASCVD event includes both non-modifiable variables; age, sex, and ethnicity, and modifiable variables such as diabetes², hypertension³, hyperlipidemia⁴, and smoking⁵. Across a population the risk of experiencing an ASCVD event varies greatly, and risk-based equations have therefore been developed to identify those who are at greatest risk of an ASCVD event risk so that treatments can be instigated appropriate to the individual's risk⁶. The landmark Framingham Heart Study was the first to demonstrate that multivariable equations could identify an individual's ASCVD risk with far greater accuracy than the existing metrics based solely on blood pressure and cholesterol⁷. Since the Framingham-based equations were first published, other equations have been developed designed to serve different populations with refined accuracy⁸⁻⁹, but in all these equations chronological age remains one of the strongest predictors of ASCVD risk. However, it is increasingly recognised that biological age¹⁰; the concept that individuals age at different rates, impacts both the risk of an individual developing a chronic disease and the severity to which they are impacted by it. That individuals age at different rates is not currently captured by traditional regression-based risk equations as they assume all individuals in the population age at the same rate. The traditional equations are therefore insensitive to the variation in individual risk that results from biological aging, and it has therefore been suggested that biological markers such as Leukocyte telomere length (LTL) and DNA methylation rates could be used to refine the prediction of an individual's ASCVD risk¹¹⁻¹⁴.

Currently LTL testing is impractical for population screening as it is an expensive test which, as a biological specimen requires careful handling within specialised laboratories. There is then arguably a need to develop other novel techniques that can personalise the ASCVD risk scores produced by the traditional ASCVD risk equations. The retina is unique in being the only part of the vascular system that is visible by non-invasive means. It is now recognised that Deep Learning (DL) can extract data from retinal images to augment the traditional

means of estimating ASCVD risk^{15,16}. We have developed an DL model (Cardiac BioAge) designed to identify those individuals within a tight chronological age band who are at increased risk of cardiac events. The aim of the study was to determine whether the results issued by our Cardiac BioAge model are consistent with the known trends of CVD risk; including the traditional biomarkers; hypertension, HbA1C, ASCVD risk and the novel biomarker LTL, in a cohort of individuals from the UK Biobank.

Methods.

Only those individuals in the UK Biobank who had LTL measurements, fundus images and relevant cardiovascular biomarker data; (Systolic, TChol/HDL, HbA1C, smoking status and diabetes status) were used in this study. The data from the UK Biobank can be accessed via a direct request to the UK Biobank (IRB UOA-862 99); and was obtained using approved data management and data transfer protocols. The research presented in this study and the datasets used in it, adhered to the principles outlined in the Declaration of Helsinki. The composition of the subset of the UK Biobank dataset used in this study is shown in Table 1. Participants in the UK Biobank were recruited from a UK general population with only approximately 5% of the UK Biobank population self-identified as having diabetes “diagnosed by doctor. 33,370 individuals in the UK Biobank had LTL data, retinal images, and relevant biodata. The demographics and the distribution of the Z adjusted log T/S LTL’s of this individual is shown in Table 1 and Figure 1.

Table 1: The demographic and risk factor makeup of the UK Biobank dataset used in this study.

	Mean	Std
Age (years)	56	8.3
Systolic Blood Pressure (mmHg)	134	18
Diastolic Blood Pressure (mmHg)	82	10.1
HbA1c (%)	5.43	0.6
Total cholesterol(mg/dL)	220	43.7

HDL cholesterol(mg/dL)	57	15.1
BMI	27.2	4.7
Sex at birth	Male	Female
	45%	55%
Current Smoker	TRUE	FALSE
	11.9%	88.1%
Diabetes (%)	4.6%	95.4%
Race/Ethnicity	White	92.9%
	Asian	2.8%
	Black	1.0%
	Other	3.3%

Figure 1 The distribution of the Z adjusted log T/S ratio LTL distribution for males and females in the UK Biobank.

Mean Z adjusted log T/S ratio LTL Males -0.105 (1.006) v Females 0.067 (0.992); P<0.001.

The Cardiac BioAge DL Model.

The cardiac BioAge model has been described previously¹⁷. In brief, this model produces a predicted Pooled Cohort Equation (PCE) derived ASCVD risk score¹⁸ and then determines how far that individuals score deviates from that of their chronological peers. The cardiac BioAge score, in effect informs whether the individuals 10-year ASCVD risk is greater or less than that of their chronological peers, and is derived using the following methodology:

- The degree of similarity of the individual’s DL model predicted ASCVD risk with the ASCVD risk score obtained from other similar aged people is determined.
- The average (chronological) age of that individuals’ closest neighbours, based on the condition of the retina as expressed by multi-dimensional features extracted from the DL model, is determined.
- The mean expected age for a person with the individual’s predicted ASCVD risk is determined.
- These data are then combined in a probabilistic manner to give a final value for the cardiac BioAge.

Individuals were divided into males and females and each cohort was then ranked by Z adjusted log T/S LTL and grouped into deciles; shortest to longest. The retinal images were then presented to the DL model and individual’s Cardiac BioAge determined and individuals within each LTL decile were then ranked by Cardiac BioAge. Next, the mean of following variables; Systolic BP, HbA1C, PCE, 10-year ASCVD risk score, derived from those individuals in the top quartile and the bottom quartile were compared and the relationship between these biomarkers and Z adjusted log T/S LTL determined using traditional correlation statistics.

Results.

The chronological age and the Cardiac BioAge issued by the DL model of males ranked by mean Z adjusted log T/S LTL decile are shown in Table 2.

Table 2. Chronological and Cardiac BioAge, categorised by mean Z adjusted log T/S LTL ratio deciles for males and females:

Z adjusted log T/S LTL ratio Decile	Males			Female		
	Mean Z adjusted log T/S LTL ratio*	Mean Chronological Age (yrs)	Mean Cardiac BioAge (yrs)	Mean Z adjusted log T/S LTL ratio*	Mean Chronological Age (yrs)	Mean Cardiac BioAge (yrs)
0	-0.4242	68.1	67.7	-0.2337	68.0	67.8
10	-0.3501	65.5	65.0	-0.1416	65.5	64.9
20	-0.2431	63.4	62.9	-0.0828	63.4	62.9

30	-0.1647	61.5	60.6	-0.0108	61.5	60.5
40	-0.1536	59.1	57.8	0.0655	59.0	57.7
50	-0.0236	56.0	54.6	0.0594	56.0	54.7
60	0.0333	53.0	51.7	0.1200	53.0	51.6
70	0.0549	49.9	48.8	0.1927	50.0	48.8
80	0.1209	46.5	45.6	0.2710	46.5	45.9
90	0.2559	42.2	41.8	0.3568	42.2	41.8

Correlation (Pearson) Males: Chronological age to LTL -0.231 ($P < 0.001$); Cardiac BioAge to LTL -0.220 ($P < 0.001$). Correlation (Pearson) Females: Chronological age to LTL -0.197 ($P < 0.001$), Cardiac BioAge to LTL -0.174 ($P < 0.001$)

The Systolic Blood pressure, HbA1C and 10-year PCE ASCVD risk score of those in individuals issued with a Cardiac BioAge score in the top quartile (Q1) and those issued with a Cardiac BioAge score in the bottom quartile of their chronological peer group, is shown in Table 3 and Figure 2. For both males and females, the mean systolic BP, mean HbA1C and the mean 10-year PCE ASCVD risk score, were all significantly higher in those individuals in the highest quartile of Cardiac BioAge compared to those in the lowest quartile of Cardiac BioAge ($P < 0.001$) Table 3. LTL were significantly shorter in males compared to females (Figure 1) and in both males and females, a worsening biomarker profile, an increased CVD risk and increasing Cardiac BioAge were inversely correlated with LTL (Table 2, Figure 2).

Table 3: Mean Biomarkers for individuals in the top quartile of Cardiac BioAge (Q1) compared to the bottom Quartile (Q4) for their chronological peer group.

	Males			Females		
	Q1 Cardiac BioAge Mean (Sd)	Q4 Cardiac BioAge Mean (Sd)	P-value	Q1 Cardiac BioAge Mean (Sd)	Q4 Cardiac BioAge Mean (Sd)	P-value
Cardiac BioAge	57 (2.0)	54 (8.4)	$P < 0.001$	57 (1.4)	52 (1.7)	$P < 0.001$
SBP (mmHg)	140 (0.8)	135 (1.1)	$P < 0.001$	136 (1.5)	127 (1.6)	$P < 0.001$
HbA1c (mmol/mol)	37 (0.5)	35 (0.6)	$P < 0.001$	36 (0.4)	34 (0.4)	$P < 0.001$
10-year ASCVD PCE risk score	8% (1.0)	7% (1.2)	$P = 0.04$	3% (0.5)	2% (0.4)	$P < 0.001$

Figure 2. Distribution of the mean biomarkers for male and female individuals in the top quartile of Cardiac BioAge (TopQ) compared to the bottom Quartile (BotQ) for their chronological peer group, categorised by Z adjusted log T/S LTL decile.

Correlation between relevant biomarker and Z adjusted log T/S LTL: Males: SBP -0.045 ($P < 0.001$), HbA1c -0.049 ($P < 0.001$), 10-year ASCVD PCE risk score -0.137 ($P < 0.001$). Females: SBP -0.0619 ($P < 0.001$), HbA1c -0.046 ($P < 0.001$), 10-year ASCVD PCE risk score -0.117 ($P < 0.001$).

Discussion.

In this cross-sectional study using a subset of individuals drawn from the UK Biobank, we found that our DL Cardiac BioAge model was able to accurately stratify individuals by the traditional CVD risk biomarkers, and that for both males and females that an elevated Cardiac BioAge score was associated with LTL shortening. In line with traditional ASCVD models, both males and females who were issued with a Cardiac BioAge in the top quartile of their chronological peer group had a significantly higher mean SBP, HbA1C and 10-year PCE ASCVD scores compared to those individuals in the bottom quartile. Consistent with other published data, we observed that a worsening biomarker profile and an increased ASCVD risk was associated with LTL shortening for both males and females^{11,12, 14, 19, 20}.

The rate of telomere shortening throughout life is determined by both endogenous (genetic) and external (non-genetic) factors^{21,22}. Although the exact mechanism behind LTL shortening and CVD remains to be elucidated, it has been hypothesised that LTL may reflect both an individual's cumulative inflammatory exposure and oxidative stress and their genetically determined capacity to repair vascular damage¹¹. Multiple confounding risk factors and reverse causation means that any observed associations between LTL and CVD should be interpreted with caution, however studies using Mendelian randomisation provide compelling evidence for a relationship between LTL shortening and an increased risk of both atherosclerotic cardiovascular events and an increased risk of hypertension^{12,23,24}. Irrespective of the mechanism by which LTL shorten, our findings indicate that whether assessed by traditional Biomarkers, or LTL, our novel Cardiac BioAge DL model could be used as a novel surrogate biomarker for cardiac Health.

A critical component to the provision of Public Health is accurate risk prediction as it enables focused preventative action and tailored disease management strategies. Accurate disease prediction also facilitates “Precision medicine” the identification of subgroups within a wider population who have different disease risks, prognosis, and responses to treatment due to differences in their habitat, physiology, and other characteristics²⁵. The utilisation of novel biomarkers, like LTL testing, in tandem with traditional measures of ASCVD risk such as the PCE equation, is one approach to the provision of more “precise” interventions to reduce the risk of ASCVD events. Although such approaches have merit, the cost, and practicalities of providing LTL testing remains a significant barrier to its widespread adoption. Arguably one of the more important contributions that AI will play within the health care ecosystem is to improve the effectiveness and precision of the traditional population-based risk predictions²⁶.²⁷ Optometry has a unique and critical role as the community provider of quality public eye health care and through clinical examination and targeted investigation, Optometrists have been providing Precision eye health care for decades. Until now Optometry’s focus has been on ocular disease, but with the emergence of AI algorithms, such as our Cardiac BioAge DL model, which have been designed specifically to stratify an individual’s risk of systemic disease by examining retinal images, there is now the potential for Optometrists to extend the provision of precision medicine beyond their traditional scope of practice. As retinal photographs are routinely captured in Optometry practices these algorithms can be deployed without significant additional investment in primary care, a feature which makes these technologies particularly relevant to low-resource settings. As such these tools have the potential to not only make ASCVD risk assessment more affordable and accessible but may also improve patient outcomes by both facilitating early intervention and increasing the public awareness of this issue.

The principal limitation of this study is that it is a cross sectional study of individuals in the UK Biobank whose LTL, retinal images and traditional biomarkers were measured at one point of time. As such, although our DL model can categorise individuals into low and high-risk groups for CVD based on the traditional biomarkers, and we observed the expected relationship between worsening biomarkers, increasing Cardiac BioAge and LTL shortening, it is not possible to determine whether these associations are causative. Further studies, using longitudinal data are therefore required to elucidate the relationship between LTL, aging, and “disease”. As is the case in all studies of DL algorithms, further studies of the algorithm in other datasets are required to demonstrate whether the results are generalisable to other

datasets and other races and ethnicities beyond those found in the UK Biobank. Finally, although LTL may be inversely associated with CVD risk in large *population*-based studies, the validity of this metric as a clinical tool to predict an *individual's* CVD risk and its magnitude remains to be proven²⁸.

Conclusion.

In this small cohort study conducted on individuals in the UK Biobank who had relevant Biomarker data, retinal images, and LTL data, increasing CVD risk; as assessed by both traditional biomarkers, ASCVD risk scoring and a DL Cardiac BioAge CVD risk model, was inversely related to LTL. At a population level our data supports the growing body of evidence that suggests that LTL shortening is a surrogate marker for increasing CVD risk and that this risk can be captured by suitably trained DL models. If these results can be replicated in other large population-based datasets, DL models like ours may offer the potential to significantly improve access to ASCVD risk detection strategies as the risk predictions these models produce do not require multiple clinical and laboratory assessments to generate an individual's ASCVD risk score.

Disclosures

Ehsan Vaghefi and David Squirrell are the co-founders of Toku Eyes. Songyang An is a member of the AI engineering team at Toku Eyes. Rini Corbett: Employment- Toku Eyes

Sources of funding

Toku Eyes has funded this study.

References:



1. Control CfD, Prevention %J CDC WONDER Online Database. Atlanta GCfDC, Prevention. Underlying cause of death, 1999–2018. 2018. <https://wonder.cdc.gov/ucd-icd10.html> Accessed December 2023.
2. Almourani R, Chinnakotla B, Patel R, et al. Diabetes and Cardiovascular Disease: an Update. *Curr Diab Rep.* 2019;19:161. doi: 10.1007/s11892-019-1239-x

3. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. *Pharmacol Res.* 2018;129:95-99. doi: 10.1016/j.phrs.2017.11.003
4. Alloubani A, Nimer R, Samara RJCCR. Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. *Current Cardiology Reviews.* 2021;17:52-66.
5. Kondo T, Nakano Y, Adachi S, Murohara T. Effects of Tobacco Smoking on Cardiovascular Disease. *Circ J.* 2019;83:1980-1985. doi: 10.1253/circj.CJ-19-0323
6. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. *Circulation.* 2019;139:e1162-e1177.
7. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. *Lancet.* 2014; 383: 999-1008. doi: 10.1016/S0140-6736(13)61752-3
8. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. *JAMA.* 2014;311:1416-23. doi: 10.1001/jama.2014.2632
9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2019;139: e1046-81. doi: 10.1161/CIR.0000000000000624
10. Comfort A. Test-battery to measure ageing-rate in man. *Lancet.* 1969 Dec 27;2(7635): 1411-4. doi: 10.1016/s0140-6736(69)90950-7. PMID: 4188291.
11. Kosmopoulos M, Chiriaco M, Stamatelopoulos K, et al. The relationship between telomere length and putative markers of vascular ageing: A systematic review and meta-analysis. *Mech Ageing Dev.* 2022 Jan;201:111604. Epub 2021 Nov 11. PMID: 34774607. <https://doi.org/10.1016/j.mad.2021.111604>.

12. Rehkopf DH, Needham BL, Lin J, et al. Leukocyte Telomere Length in Relation to 17 Biomarkers of Cardiovascular Disease Risk: A Cross-Sectional Study of US Adults. *PLoS Med.* 2016 Nov 29;13(11):e1002188. <https://doi.org/10.1371/journal.pmed.1002188>. PMID: 27898678; PMCID: PMC5127504.
13. Sagris M, Theofilis P, Antonopoulos AS, et al. Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target. *Int J Mol Sci.* 2022 Dec 16;23(24):16010. <https://doi.org/10.3390/ijms232416010>. PMID: 36555658; PMCID: PMC9781338.
14. Ylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. *EBioMedicine.* 2017 Jul;21:29-36. <https://doi.org/10.1016/j.ebiom.2017.03.046>. Epub 2017 Apr 1. PMID: 28396265; PMCID: PMC5514388.
15. Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. *Nat Biomed Eng.* 2018 Mar;2(3):158-64. <https://doi.org/10.1038/s41551-018-0195-0>. Epub 2018 Feb 19. PMID: 31015713.
16. Miyazawa AA. Artificial intelligence: the future for cardiology. *Heart.* 2019 Aug;105(15):1214. <https://doi.org/10.1136/heartjnl-2018-314464>. Epub 2019 Jan 12. PMID: 30636218.
17. Ehsan Vaghefi, David Squirrell, Song Yang, Songyang An, Li Xie, Mary K. Durbin, Huiyuan Hou, John Marshall, Jacqueline Shreibati, Michael V McConnell, Matthew Budoff, Development and validation of a deep-learning model to predict 10-year ASCVD risk from retinal images using the UK Biobank and EyePACS 10K datasets doi: <https://doi.org/10.1101/2023.09.20.23295870>
18. Grundy SM, Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. *JAMA Cardiol.* 2019 Jun 1;4(6):589-91. <https://doi.org/10.1001/jamacardio.2019.0911>. PMID: 30994869.
19. Hoffmann J, Richardson G., Haendeler, J et al. Telomerase as a therapeutic target in cardiovascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 41(3), 1047–61. <https://doi.org/10.1161/atvbaha.120.315695>. Epub 2021 Jan 28. PMID: 33504179.

20. Schneider CV, Schneider KM, Teumer A et al. Association of telomere length with risk of disease and mortality. *JAMA Intern Med.* 2022 Mar 1;182(3):291-300.
<https://doi.org/10.1001/jamainternmed.2021.7804> PMID: 35040871; PMCID: PMC8767489.
21. Martínez P, Blasco MA. Heart-Breaking Telomeres. *Circ Res.* 2018 Sep 14;123(7):787-802. <https://doi.org/10.1161/circresaha.118.312202>. PMID: 30355079.
22. Scheller Madrid A, Rode L, Nordestgaard BG, & Bojesen, SE. Short telomere length and ischemic heart disease: Observational and genetic studies in 290 022 individuals. *Clin Chem.* 2016 Aug;62(8):1140-9. <https://doi.org/10.1373/clinchem.2016.258566>. Epub 2016 Jun 3. PMID: 27259814.
23. Deng Y, Li Q, Zhou F, et al. Telomere length and the risk of cardiovascular diseases: A Mendelian randomization study. *Front Cardiovasc Med.* 2022 Oct 24;9:1012615.
<https://doi.org/10.3389/fcvm.2022.1012615>. PMID: 36352846; PMCID: PMC9637552.
24. Zhan Y, Hägg S. Telomere length and cardiovascular disease risk. *Curr Opin Cardiol.* 2019 May;34(3):270-74. <https://doi.org/10.1097/hco.0000000000000613> PMID: 30747731.
25. Deng J, Hartung T, Capobianco E, et al. Editorial: Artificial Intelligence for Precision Medicine. *Front. Artif. Intell.* 4:834645. *Front. Artif. Intell.*, 21 January 2022. Sec. Medicine and Public Health <https://doi.org/10.3389/frai.2021.834645>
26. Olawade DB, Wada OJ, David-Olawade AC, et al (2023) Using artificial intelligence to improve public health: a narrative review. *Front. Public Health* 11:1196397.
<https://doi.org/10.3389/fpubh.2023.1196397>
27. [Precision Medicine: Using Artificial Intelligence to Improve Diagnostics and Healthcare](#)
Whirl-Carrillo E, Brenner S, Chen J et al. *Biocomputing* 2023. November 2022, 257-262
https://doi.org/10.1142/9789811270611_0024
28. Herrmann, W., & Herrmann, M. (2020). The importance of telomere shortening for atherosclerosis and mortality. *J Cardiovasc Dev Dis.* 2020 Aug 6;7(3):29.
<https://doi.org/10.3390/jcdd7030029>. PMID: 32781553; PMCID: PMC7570376

WITHDRAWN
see manuscript DOI for details




Male

Systolic Blood Pressure




Female

Systolic Blood Pressure




Male

LDL-C




Female

LDL-C



Male

ASCVD PDI* (years)



Female

ASCVD PDI* (years)

